Shifamed portfolio company Adona Medical today announced the introduction of its next-generation heart failure platform.
Brian Fahey, Adona Medical co-founder and CEO, unveiled the platform at the CSI Frankfurt 2023 conference. There, Fahey introduced the developing interatrial shunt technology in a presentation.
The Adona heart failure management platform features an adjustable interatrial shunt with integrated bi-atrial pressure monitoring. Its shunt flow channel offers an adaptable geometry capable of growing larger or minimizing at any time post-implant. This can help optimize shunting flow or dose for patient needs at the time of the initial procedure. It then can adjust as the patient’s condition evolves over time.
Integrated sensors included in the platform capture pressure readings from both the left and right atria multiple times per day. These sensors don’t require patient interaction, Adona says. Daily readings from the sensors help give physicians a more complete understanding of a patient’s hemodynamic status. They also augment shunt therapy by enabling more informed pharmaceutical management, according to a news release.
Fahey called the company “thrilled” to present the progress it made on its heart failure platform at CSI Frankfurt.
“Adona Medical is committed to providing heart failure patients and physicians with technologies that address the shortcomings of currently available solutions. You’d struggle to find a physician comfortable with deciding on a fixed dose of medication for a patient and never being able to alter it in the future or monitor its effects, but this is comparable to the use case for interatrial shunts currently under clinical investigation,” said Fahey. “At Adona, we believe that patient care can be pushed forward by a customizable and adjustable shunting approach combined with an advanced hemodynamic monitoring solution.”